Clin Osteol 2020; 25(2): 93-98

Treatment of atypical femoral fracture with teriparatide: case reportCase reports

Rosa Jan1, Bouda Václav2, Kasalický Petr1
1 Osteocentrum, Affidea Praha s. r. o.
2 Oddělení zobrazovacích metod, Affidea Praha s. r. o.

Atypická fraktura femoru (AFF) je vzácným nežádoucím účinkem dlouhodobé aplikace bisfosfonátů nebo denosumabu. Předkládáme popis případu pacientky léčené pro osteoporózu bisfosfonáty (celkem 104 měsíců). Na základě prodromálních příznaků byla zobrazovacími metodami (RTG, MRI, kostní scintigrafie) diagnostikována inkompletní atypická fraktura levé kosti stehenní. Přerušení podávání bisfosfonátu, odlehčení končetiny a šestiměsíční aplikace teriparatidu vedly ke zhojení zlomeniny. U pacientů užívajících antiresorpční léčbu osteoporózy po dobu delší než 4 roky je nezbytné pravidelné dotazování na prodromální příznaky AFF.

Keywords: teriparatide; bisphosphonates; atypical femoral fracture

Published: December 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jan R, Bouda V, Kasalický P. Treatment of atypical femoral fracture with teriparatide: case report. Clinical Osteology. 2020;25(2):93-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Armamento-Villareal R, Napoli N. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. NEJM 2006; 355(9): 2048. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc062268>. Go to original source...
    2. Black DM, Abrahamsen Bo, Bouxsein ML et al. Atypical Femur Fractures -⁠ Review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocrine Rev 2019; 40(2): 333-368. Dostupné z DOI: <http://dx.doi.org/10.1210/er.2018-00001>. Go to original source...
    3. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29(1): 1-23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>. Go to original source...
    4. Bala A, Gaillard F. Insufficiency fracture. Dostupné z WWW: <https://radiopaedia.org/articles/insufficiency-fracture>.
    5. Shane E, Burr D, Ebeling PR et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2010; 25(11): 2267-2294. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.253>. Go to original source...
    6. Rizzoli R, Akesson K, Bouxsein M et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European society on clinical and economic aspects of osteoporosis and osteoarthritis and International osteoporosis foundation working group report. Osteoporos Int 2011; 22(2): 373-390. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-010-1453-5>. Go to original source...
    7. Schilcher J, Koeppen V, Aspenberg P et al. Risk of atypical femoral fracture during and after bisphosphonate use Full report of a nationwide study. Acta Orthop 2015; 86(1): 100-107. Dostupné z DOI: <http://dx.doi.org/10.3109/17453674.2015.1004149>. Go to original source...
    8. van de Laarschot DM, Smits AAA, Buitendijk SKC et al. Scrrening for atypical femur fractures using extended femur scans by DXA. J Bone Mineral Res 2017;32(8): 1632-1639. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.3164>. Go to original source...
    9. Chang-Wug O, Jong-Keon O, Ki-Chul P et al. Prophylactic Nailing of Incomplete Atypical Femoral Fractures. Sci World J 2013; 450148. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/450148>. Go to original source...
    10. Schemitsch C, Kuzky P, McKee M. Atypical femoral fracture despite prophylactic intramedullary nailing: A case report. JBJS Case Connect 2015; 5(3): e57. Dostupné z DOI: <http://dx.doi.org/10.2106/JBJS.CC.N.00066>. Go to original source...
    11. van de Laarschot DM, McKenna M, Zillikens MC. Medical management of atypical femur fractures: a systematic review. J Clin Endocrinol Metab 2020; 105(5): 1682-1699. Dostupné z DOI: <http://doi:10.1210/clinem/dgz295>. Go to original source...
    12. Obermayer-Pietsch B, Marin F, McCloskey EV et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; 23(10): 1591-1600. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.080506>. Go to original source...
    13. Krege JH, Lane, NE, Harris JM et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014; 25(9): 2159-2171. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-014-2646-0>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.